Age‐related Macular Degeneration Market Size, Trends, Revenue, Demand and Future Trend - DhananjayPinge/technoresearch GitHub Wiki
The Global Age-Related Macular Degeneration Market is experiencing robust growth, with current valuation estimated at $8.9 billion in 2024 and projected to reach $14.5 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.2% during the forecast period, according to recent market analysis.
Download Free Sample Report PDF @ https://www.econmarketresearch.com/request-sample/EMR00481
Market Overview
Age-related Macular Degeneration continues to be the leading cause of severe vision impairment and blindness among individuals over 50 years of age in developed countries. The disease's prevalence has created a substantial and expanding market for diagnostic technologies, therapeutics, and vision aids designed to manage both dry and wet forms of AMD.
Market Segmentation Analysis
The AMD market is segmented by disease type, product type, route of administration, end-user, and geographical region.
By Disease Type:
Dry AMD currently accounts for approximately 85-90% of diagnosed cases but represents only 35% of the market value due to limited treatment options. Wet AMD, despite affecting only 10-15% of patients, commands approximately 65% of market revenue due to higher-priced treatment modalities and more aggressive intervention protocols. By Product Type:
Anti-VEGF therapies dominate the market with a 72% share, led by established treatments such as Eylea (aflibercept), Lucentis (ranibizumab), and newer biosimilar alternatives. Photodynamic therapies maintain a 12% market share, primarily used as adjunctive treatments. Small molecule therapies are rapidly growing at 18%, with oral medications and complement inhibitors showing particular promise. Implantable devices, laser treatments, and nutritional supplements collectively represent the remaining 16% of the market. By End User:
Hospitals and specialty eye clinics capture 63% of the market. Ambulatory surgical centers account for 25%. Research institutions and other healthcare facilities represent the remaining 12%. Market Growth Analysis
The AMD market is propelled by several key factors:
The expanding elderly population worldwide, with particularly sharp increases in Asia and Latin America where AMD diagnosis rates are rising rapidly. Improved diagnostic capabilities, including advanced imaging technologies and artificial intelligence-assisted screening, are identifying AMD at earlier stages when intervention is most effective. A robust pipeline of over 35 drug candidates in various stages of clinical development, with several breakthrough designations granted for novel mechanisms of action targeting geographic atrophy and early-stage dry AMD. Increased healthcare expenditure on age-related conditions, with payers recognizing the economic benefits of preserving vision in aging populations. Growing awareness and screening programs in emerging markets, reducing the diagnostic gap that has historically limited market penetration outside North America and Europe. Market Trends
Several transformative trends are reshaping the competitive landscape:
The shift toward extended-duration formulations of anti-VEGF therapies has gained significant momentum, with treatments requiring injections every 12-16 weeks rather than monthly, dramatically improving patient compliance and quality of life.
Home monitoring technologies leveraging smartphone-based vision testing are creating new market segments for early detection and disease progression monitoring, expanding the total addressable market.
Gene therapies have entered late-stage trials for both wet and dry AMD, promising one-time treatments that could fundamentally disrupt current treatment paradigms and pricing structures.
Combination therapies targeting multiple pathways simultaneously show superior efficacy in preliminary studies, potentially creating premium-priced treatment options for refractory cases.
Competitive Landscape
The market remains dominated by established pharmaceutical companies including Regeneron Pharmaceuticals, Novartis, Roche, and Bayer, which collectively control approximately 68% of market share. However, this dominance is increasingly challenged by:
Emerging biotech companies with novel therapeutic approaches, particularly for treating geographic atrophy and early-stage dry AMD. Medical device manufacturers developing innovative drug delivery systems that reduce treatment burden. Digital health companies creating AI-driven diagnostic and monitoring solutions. Generic manufacturers introducing biosimilar versions of first-generation anti-VEGF treatments as patents expire. Market Opportunities
Significant opportunities exist in several underdeveloped segments: The geographic atrophy market represents a largely untapped opportunity worth an estimated $3.2 billion, with recently approved treatments just beginning to address this high-need population. Prophylactic interventions for high-risk patients with intermediate dry AMD constitute an emerging preventative market estimated at $1.8 billion. Combination therapy regimens offer premium pricing potential for difficult-to-treat cases and patients showing diminished response to monotherapies. Lower-cost treatment options for emerging markets, where current branded therapies remain prohibitively expensive, represent a volume-driven growth opportunity. Research Insights
Recent research highlights several developments poised to impact the market: Biomarker identification is enabling more personalized treatment approaches, potentially improving outcomes while optimizing healthcare resource utilization. The microbiome's role in AMD development and progression has opened new avenues for intervention through both nutritional and pharmacological approaches. Sustained drug delivery platforms utilizing biodegradable implants show promise in dramatically reducing treatment burden while maintaining efficacy.
Read Full Research Report @ https://www.econmarketresearch.com/industry-report/age-related-macular-degeneration-amd-market/
About Us:
Econ Market Research, we are dedicated to delivering precise, actionable market intelligence that drives business success. Our team of expert analysts combines advanced data analytics with deep sector knowledge to provide comprehensive market insights. We specialize in custom research solutions, competitive analysis, and strategic forecasting across diverse industries. Our commitment to quality and accuracy has earned us the trust of Fortune companies, startups, and government agencies worldwide. Through innovative methodologies and rigorous analysis, we empower our clients to make informed decisions that shape their future growth and market position.
Contact Us:
Econ Market Research
Age-related Macular Degeneration Market, Age-related Macular Degeneration Market Size, Age-related Macular Degeneration Market Share, Age-related Macular Degeneration Market Growth
Our Related Report:
Female Fragrance Market Trends